Management

Company

Board
Management
IPR
Collaborations

Pharma Holdings Management

Pharma Holdings is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical functions such as product development, regulatory affairs, design and execution of clinical trials. Agir AS is retained for administration and project management.

Christian Lütken, CEO

Christian Lütken holds an MD from the University of Oslo and has several
years of experience in the fields of pediatrics, family medicine, emergency medicine and occupational medicine. He has management experience as previous Head of Department in a private healthcare company. In recent years Christian has been working in DNB’s Global Healthcare team financing healthcare companies globally, and also working closely with the Norwegian healthcare startup scene comprising all subsegments of the healthcare industry including med.tech, pharma, bio tech, digital health and healthcare services.

Torsteinn Erlingsson, CFO

Mr. Erlingsson has been with Pharma Holdings AS since 2018. He holds a
Master Science degree in Fishery Science from UiT, the Arctic University of Norway. He has more than 25 years of experience from corporate finance and business development. In his tenure in corporate finance Erlingsson worked on several biotech transactions, and in Pharma Holdings Mr. Erlingsson has secured equity financing for the relaunch of the development of our lead drug candidate.
Edvard Christian Fuglset Dahl

Edvard Christian Fuglset Dahl, Head of Business Development (in transit)

Mr Dahl has a bachelor in food&dairy technology, and have more than 25 years’ experience from health care industry, including pharma, medical devices and diagnostics, in different roles comprising sales, marketing and business development. His track record includes inter alia establishing a pharmaceutical company in Norway, and having scaled a digital diagnostic company internationally. Further, he has documented results in establishing distributor networks, distributor contracts, both exclusive and non-exclusive and has track record from merger & acquisitions – from screening fase, negotiations and final take over. His last position in Inven2 included working with health care startups, accelerating their commercial potential and contributing in key processes such as finding potential licensing partners.
Niklas Hammarstedt

Niklas Hammarstedt, Chief Quality Officer

Mr. Hammarstedt has a M.Sc. in chemistry, chemical and pharmaceutical engineering from KTH, the royal institute of technology in Stockholm Sweden.
He has more than 10 years of experience from working within the pharmaceutical and biotechnological industries specifically in roles within Quality Control, production management, project management and Quality Assurance.
The majority of his experience was gathered working at Octapharma AB starting in QC, then as Head of Production Documentation managing master batch records, batch record review and company SOPs, and finally working in QA. In his last position, as CQO at Atlas Antibodies AB, Niklas has been focusing on defining and building quality routines into a company-wide quality management system, from a compliance and sustainability perspective, combined with adapting best practices. Process compliance and efficiency together with supportive system implementation, integration and optimization were key needs and focus areas throughout precious positions.

Johnny Ryvoll, Vice President Projects

Mr. Ryvoll has been with Pharma Holdings since 2018. He holds a MBA from University of Washington, Foster School of Business, and also a degree in Electrical Engineering (Siv. Ing.). He has more than 25 years of experience from corporate finance, project management and business development. In his tenure in corporate finance Mr. Ryvoll worked on several biotech transactions. In his time in Pharma Holdings he has built a network of high-quality contract research organizations and contract manufacturing capacity as well as networks of experienced advisors in all critical functions for the company such as product development, regulatory affairs, design and execution of clinical trials.

Rolf EngstadContracted CMC Lead

Rolf E. Engstad holds a PhD in immunology from the University of Tromsø and has more than 30 years of experience in research and development of pharmaceutical product candidates. He is approved as a qualified person (QP) and has been responsible for securing the manufacture and the pharmaceutical quality of clinical trial products.
Engstad was chief scientific officer (CSO) in Biotec Pharmacon for almost 20 years and in charge of the successful development of pharmaceutical and medical device products, as well as responsible for pre-clinical and clinical studies. He has longstanding research collaborations with international institutions like the Charité in Berlin, the Memorial Sloan Kettering Cancer Centre, and the Mount Sinai Hospital, both New York, as well as with many Norwegian universities and research institutes. Engstad is also the inventor of more than 20 granted patents and patent applications.